Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Department of Drug Design and Optimization, Saarland University, Campus C2_3, D-66123 Saarbrücken, Germany.
ACS Chem Biol. 2013 Apr 19;8(4):758-66. doi: 10.1021/cb3005758. Epub 2013 Jan 30.
The number of bacterial strains that are resistant against antibiotics increased dramatically during the past decades. This fact stresses the urgent need for the development of new antibacterial agents with novel modes of action targeting essential enzymes such as RNA polymerase (RNAP). Bacterial RNAP is a large multi-subunit complex consisting of a core enzyme (subunits: α(2)ββ'ω) and a dissociable sigma factor (σ(70); holo enzyme: α(2)ββ'ωσ(70)) that is responsible for promoter recognition and transcription initiation. The interface between core RNAP and σ(70) represents a promising binding site. Nevertheless, detailed studies investigating its druggability are rare. Compounds binding to this region could inhibit this protein-protein interaction and thus holo enzyme formation, resulting in inhibition of transcription initiation. Sixteen peptides covering different regions of the Escherichia coli σ(70):core interface were designed; some of them-all derived from σ(70) 2.2 region-led to a strong RNAP inhibition. Indeed, an ELISA-based experiment confirmed the most active peptide P07 to inhibit the σ(70):core interaction. Furthermore, an abortive transcription assay revealed that P07 impedes transcription initiation. In order to study the mechanism of action of P07 in more detail, molecular dynamics simulations and a rational amino acid replacement study were performed, leading to the conclusion that P07 binds to the coiled-coil region in β' and that its flexible N-terminus inhibits the enzyme by interaction with the β' lid-rudder-system (LRS). This work revisits the β' coiled-coil as a hot spot for the protein-protein interaction inhibition and expands it by introduction of the LRS as target site.
在过去几十年中,对抗生素具有耐药性的细菌菌株数量急剧增加。这一事实强调了迫切需要开发新的抗菌药物,这些药物具有针对 RNA 聚合酶 (RNAP) 等必需酶的新型作用模式。细菌 RNAP 是一个由核心酶(亚基:α(2)ββ'ω)和一个可分离的 sigma 因子(σ(70);全酶:α(2)ββ'ωσ(70))组成的大型多亚基复合物,负责启动子识别和转录起始。核心 RNAP 和 σ(70)之间的界面代表了一个有前途的结合位点。然而,对其可药性进行详细研究的情况很少。与该区域结合的化合物可以抑制这种蛋白质-蛋白质相互作用,从而抑制全酶形成,导致转录起始抑制。设计了覆盖大肠杆菌 σ(70):核心界面不同区域的 16 个肽;其中一些 - 全部来自 σ(70)2.2 区域 - 导致 RNAP 强烈抑制。事实上,基于 ELISA 的实验证实了最活跃的肽 P07 可以抑制 σ(70):核心相互作用。此外,一个流产转录测定表明 P07 阻碍转录起始。为了更详细地研究 P07 的作用机制,进行了分子动力学模拟和合理的氨基酸替换研究,得出的结论是 P07 结合到β'中的卷曲螺旋区,其柔性 N 端通过与β'盖舵系统(LRS)相互作用抑制酶。这项工作重新审视了β'卷曲螺旋作为蛋白质-蛋白质相互作用抑制的热点,并通过引入 LRS 作为靶位点来扩展它。